Alert for Alto Neuroscience investors: Law firm Faruqi & Faruqi warns about an impending class-action lawsuit with a lead plaintiff deadline slated for September 19, 2025, designated as ANRO.
In a recent development, Faruqi & Faruqi, LLP, a leading national securities law firm, has announced an investigation into potential claims against Alto Neuroscience, Inc. The investigation concerns violations of federal securities laws by Alto and its executives.
The investigation was prompted by a series of events, including the sudden drop in Alto's stock price. On October 22, 2024, Alto announced topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for Major Depressive Disorder (MDD), which did not meet its primary endpoint. Consequently, Alto's stock price fell $10.17 per share, or 69.99%, after the announcement.
Jeffries, a well-known financial institution, also lowered its price target for Alto Neuroscience to $17 from $33, citing concerns about ALTO-100's data and questioning Alto's overall biomarker approach to Central Nervous System (CNS) disorders and psychiatry. The complaint further alleges that Alto's business and/or financial prospects were overstated, both in terms of its clinical, regulatory, and commercial prospects.
Faruqi & Faruqi, LLP encourages anyone with information about Alto's conduct to contact the firm. Investors who purchased or otherwise acquired Alto stock during the specified period and would like to discuss their legal rights can contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The firm can also be reached through its website, www.faruqilaw.com, or on LinkedIn, X, and Facebook for updates.
It is important to note that the deadline to seek the role of lead plaintiff in a federal securities class action against Alto is September 19, 2025. Any member of the putative class can move the Court to serve as lead plaintiff through counsel of their choice. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
In early September 2025, Alto Neuroscience, Inc. filed for bankruptcy protection; however, the specific company initiating the bankruptcy protection request against Alto Neuroscience, Inc. is not publicly documented.
For more information about the Alto Neuroscience class action, visit www.faruqilaw.com/ANRO. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
As the investigation continues, investors are encouraged to stay informed and seek legal advice if they believe they have been affected by these alleged violations.
